Home » Topics » BioWorld Science

BioWorld Science
RSS

Patient enrollment ongoing in phase I/II study of SOBI-003 in pediatric MPS IIIA

July 2, 2018

First-in-human study of D-0502 is enrolling participants

July 2, 2018

Ocular Therapeutix announces NDA resubmission to the FDA for Dextenza

July 2, 2018

Laboratorios del Dr. Esteve presents new pyridazine derivatives for pain

July 2, 2018

Positive CHMP opinion granted for Mepsevii for the treatment of mucopolysaccharidosis VII

July 2, 2018

Cefepime/VNRX-5133 fixed-dose combination shows promise against resistant Gram-negative bacteria

July 2, 2018

FDA lifts clinical hold for phase Ib trial of APTO-253

July 2, 2018

Epizyme patents KAT5 and KAT6A inhibitors

July 2, 2018

Vyxeos receives positive CHMP opinion

July 2, 2018

TAK-228 demonstrates potential for the treatment of NFE2L2-mutant squamous cell lung cancer

July 2, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma
BioWorld Science
Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is...